Figure 7.

Adjusted* cumulative weighted predicted costs for among patients with metastatic non-small-cell lung cancer epidermal growth factor receptor activating mutation that progress early (months 0–12) versus late (months 13–36) after initiation on a first-line epidermal growth factor receptor tyrosine kinase inhibitor. (A) Medical services healthcare costs (excluding antineoplastic treatment costs). (B) Total healthcare costs (medical services + antineoplastic treatment). (C) Antineoplastic treatment costs.

*Models adjusted for age, gender, region, health plan type, year of first line treatment initiation, comorbidity index score and first line EGFR TKI.

**Statistical significance reported for each month has some variation, p-values are less than 0.05 for all months in model a.

EGFRm: Epidermal growth factor receptor activating mutation; mNSCLC: Metastatic non-small-cell lung cancer; TKI: Tyrosine kinase inhibitor.